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Abstract
Chronic pain is a highly prevalent and poorly managed human health problem. We used 
microarray-based expression genomics in 25 inbred mouse strains to identify dorsal root ganglion 
(DRG)-expressed genetic contributors to mechanical allodynia, a prominent symptom of chronic 
pain. We identified expression levels of Chrna6, which encodes the α6 subunit of the nicotinic 
acetylcholine receptor (nAChR), as highly associated with allodynia. We confirmed the 
importance of α6* (i.e., α6-containing) nAChRs by analyzing both gain- and loss-of-function 
mutants. We find that mechanical allodynia associated with neuropathic and inflammatory injuries 
is significantly altered in α6* mutants, and that α6* but not α4* nicotinic receptors are absolutely 
required for peripheral and/or spinal nicotine analgesia. Furthermore, we show that Chrna6’s role 
in analgesia is at least partially due to direct interaction and cross-inhibition of α6* nAChRs with 
P2X2/3 receptors in DRG nociceptors. Finally, we establish relevance of our results to humans by 
the observation of genetic association in patients suffering from chronic postsurgical pain and 
temporomandibular pain.
INTRODUCTION
Chronic pain in the clinic manifests itself mainly in the form of spontaneous pain and 
mechanical allodynia, a sensitized response to an innocuous stimulus. Patients suffering 
from the latter symptom sometimes find clothing touching their skin or a light breeze to be 
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very painful. Current medications are mostly inadequate to treat such symptoms, and an in-
depth understanding of molecular mechanisms of mechanical allodynia is still lacking.
Here we used an unbiased approach to identify genes involved in mechanical allodynia. 
Specifically, we correlated mechanical allodynia phenotypes of 25 inbred mouse strains to 
genome-wide gene expression levels in dorsal root ganglia of these strains. This expression 
genomics strategy has been adopted previously in pain research (1–4), but using a much 
smaller number of strains. We provide evidence for the expression of the Chrna6 gene 
encoding the nicotinic α6 subunit as a major determinant of variable mechanical allodynia 
after nerve injury.
Neuronal nAChRs are hetero- or homopentameric ligand-gated ion channels composed of α 
(α2–α7, −9 and −10) and β (β2–β4) subunits. They have been the target of analgesic drug 
discovery for many years, with progress being hindered by a narrow therapeutic window and 
side effects. Attention has been focused largely on α4β2* (i.e., α4- and β2-containing) 
nAChRs (5), the most highly expressed subtype in the CNS but effects on pain of α3* (6), 
α7 (7) and α9* (8, 9) nAChRs have also been demonstrated. The α6* nAChRs have been 
mysterious until the recent elucidation of their involvement in the mesolimbic dopaminergic 
system, in which they activate dopamine neurons causing locomotor hyperactivity (10), and 
visual system, in which they modulate glutamate and γ-amino-butyric acid release in the 
superior colliculus (11). The α6 subunit is known to be localized in sensory ganglia (12–15). 
There are no reported agonists that discriminate well between α6* and α4* nAChRs, raising 
the possibility that the α6 subunit plays an unappreciated role in nicotinic analgesia in the 
spinal cord or periphery.
RESULTS
Association between DRG Chrna6 expression and neuropathic mechanical allodynia in 
mice
Mechanical allodynia induced by spared nerve injury (SNI) was quantified in 25 inbred 
mouse strains using von Frey filaments, and compared to basal DRG expression of 45,101 
mRNA transcripts using microarray gene-expression profiling (Affymetrix MOE430v2 chip) 
in these same 25 strains. All strains displayed ipsilateral allodynia (Fig. 1A,B, fig. S1), but 
highly significant effects of strain (F24,89=9.1, P<0.001) and strain x repeated measures 
interaction (F144,534=2.2, P<0.001) were observed. That is, strains displayed different 
extents and time courses of allodynia (see fig. S1). A significant strain x sex x repeated 
measures interaction (F144,534=1.4, P<0.05, Greenhouse-Geisser corrected) was also 
evinced. This interaction appeared to be largely due to robust sex differences in the SM/J 
(see below) and C3H/HeJ strains (16).
Correlating the overall allodynia data (Fig. 1B) with the Affymetrix chip data revealed 10 
correlations at the P<0.005 level (uncorrected) (Fig. 1C). The top two highest correlations 
(in either direction), genome-wide, were with two different probes for Chrna6 (r=−0.75 and 
r=−0.72) (Fig. 1C,D) such that higher expression of Chrna6 was associated with lower levels 
of allodynia development. These associations are both significant at 0.05 using false 
discovery rate correction for multiple comparisons; no other associations were significant, 
Wieskopf et al. Page 3
Sci Transl Med. Author manuscript; available in PMC 2016 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and thus no attempts were made to evaluate the candidacy of the other genes in Fig. 1C. The 
Chrna6 correlations were sex-dependent, being considerably higher in males (r=−0.67, 
−0.63) than in females (r=−0.37, −0.33). Table S1 shows strain-dependent expression levels 
of all Chrn* genes coding for nicotinic subunits; none other than Chrna6 featured suggestive 
correlations with allodynia or baseline nociception. Average DRG expression of Chrn* 
genes across-strain is shown in Fig. 1E. As can be appreciated by the error bar, Chrna6 
displayed more genotypic variation than any other subunit gene; with a coefficient of 
variation ≈50% higher than the next most variable subunit (Chrnb3) and more than 10-fold 
higher than Chrna6 (see table S1).
Conventional haplotype mapping was also performed, correlating mechanical allodynia 
strain means with approximately 156,000 genomic haplotypes (17). Of the top 10 correlated 
haplotypes genome-wide (see table S2), two of them were located just upstream of the 
Chrna6 gene on mouse chromosome 8. Other potentially associated genes include Kcnv1, 
Ubc, Aldh7a1, Gfra2, and Chrna3 (located very near Chrna6 on chromosome 14).
Chrna6 is expressed in a subset of DRG neurons
qPCR experiments revealed detectable expression of Chrna6 mRNA in whole brain, DRG, 
and eye, but not lung (Table 1). However, relative expression levels varied in these tissues, 
with DRG expression >10-fold higher than expression in whole brain and >2-fold higher 
than in the eye (both P<0.001). In situ hybridizations performed at the Allen Institute for 
Brain Science showed the presence of Chrna6 expression in small- to medium-diameter 
DRG neurons (not shown), and this was confirmed using α6*-GFP BAC transgenic mice 
(Fig. 2). DRGs were double-stained with GFP and neuronal sensory marker antibodies, 
including NF200 that marks mostly myelinated Aβ neurons, as well as IB4 and CGRP that 
mark distinct populations of nociceptive neurons. Sixty-six percent of the GFP-positive 
neurons also expressed NF200 (203/306 out of 840 total neurons counted), whereas 37% of 
NF200 positive neurons expressed GFP (123/336). Twenty-six percent of the GFP 
population also stained for IB4 (135/512 out of 1286), while 58% of IB4 population 
expressed GFP (169/293). Finally, 8% of the GFP neurons also expressed CGRP (39/496 
from a total of 1213), while 35% of CGRP positive neurons expressed GFP (91/258). These 
results suggest that Chrna6 is expressed in various functionally distinct DRG subtypes. A 
previous study observed a similar range of co-labelling of Chrna6 mRNA and peptidergic 
nociceptor-related (i.e., CGRP or transient receptor potential, V1) immunoreactivity in rat 
trigeminal ganglion (18).
We also confirmed genotype- and sex-dependent Chrna6 expression in the DRG in three 
mouse strains using qPCR. As was observed in the gene chip experiment (fig. S2A), Chrna6 
expression appeared to be robustly strain-dependent, and in one strain, strongly sex-
dependent, with male SM/J mice displaying >30-fold higher expression than female mice of 
the same strain (fig. S2B). This was an intriguing observation, since we also observed a 
marked sex difference in SM/J mice in the development of mechanical allodynia after spared 
nerve injury (female > male; sex x repeated measures: F6,78=3.7, P<0.005) (fig. S2C).
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Nerve injury-induced down-regulation of Chrna6 and mechanical allodynia
In an independently performed experiment to identify genes associated with chronic pain 
(2), microarray gene expression profiling (also using the Affymetrix MOE430v2 chip) was 
performed in the DRGs of five inbred mouse strains after sham surgery or spinal nerve 
ligation (SNL), another common preclinical assay of neuropathic pain associated with 
mechanical allodynia. The two Chrna6 probe sets appeared in the top 10 highest fold-
regulations by SNL compared to sham surgery (fig. S3A), with down-regulations of 67.3-
fold and 41.6-fold, respectively. The downregulation was highly correlated (r=0.90, P<0.05) 
with basal DRG expression (fig. S3B), but even after downregulation by SNL a strongly 
negative correlation (r=−0.93) between Chrna6 expression and allodynia was observed in the 
three strains tested behaviorally (fig. S3C), suggesting that Chrna6 expression protects 
against allodynia after nerve injury as well.
Confirmation of Chrna6 involvement in mutant mice
To provide causal evidence of the involvement of the α6 subunit in neuropathic pain, we 
tested transgenic Chrna6 null mutant mice (19) and Chrna6 gain-of-function L9’S mutant 
mice (10) for mechanical allodynia after SNI. To investigate whether α6* nAChRs play a 
similar role in chronic inflammatory pain, we also tested these mutants for mechanical 
allodynia after intraplantar CFA injection (Fig. 3). All genotypes displayed expected time 
courses of allodynia. For both SNI and CFA, Chrna6 KO mice displayed higher overall 
levels of allodynia compared to WT mice (t21=3.2, P<0.005, t10=2.5, P<0.05, respectively). 
For both SNI and CFA, Chrna6 L9’S mutant mice displayed lower overall levels of allodynia 
compared to their WT controls (t9=3.0, P=0.01, t16=2.2, P<0.05, respectively). There were 
no significant genotype x sex interactions observed in any data set, although strong trends 
were noted for genotype differences being larger in male versus female mice (not shown). In 
an experiment performed independently, in a different laboratory, using Chrna6 KO mice 
and another neuropathic assay (CCI), the increased mechanical allodynia of KO mice was 
confirmed (fig. S4A). A separate head-to-head experiment using CCI and CFA in Chrna6 
and Chrna4 KO mice confirmed the significantly increased allodynia in Chrna6 KOs, but 
revealed no differences between Chrna4 KOs and their wildtype controls (fig. S4B,C). The 
α6 subunit appears to play a highly specific role in the modulation of mechanical allodynia, 
as Chrna6 KO mice displayed statistically equivalent responses to wildtype mice on a 
battery of acute and tonic nociceptive assays (fig. S5).
Relevance of α6 to anti-allodynic effects of nicotine
Nicotine itself exerts anti-allodynic effects after both inflammatory and neuropathic injuries 
(5). We tested the ability of systemic, intracerebroventricular (i.c.v.), intrathecal (i.t.) and 
peripheral (intraplantar; i.pl.) (−)-nicotine to reverse mechanical allodynia produced by both 
SNI and CFA in WT, KO and L9’S mice. Although potency and efficacy varied by route of 
administration, nicotine was significantly and dose-dependently effective against both types 
of allodynia in wildtype mice by all injection routes (Fig. 4; table S3). Gain-of-function 
L9’S mutants showed similar or significantly increased efficacy, but Chrna6 KO mice 
displayed no significant nicotine-induced anti-allodynia in either assay by any route. We 
then performed a head-to-head comparison of supraspinal, spinal and peripheral nicotine-
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induced anti-allodynia (25 μg, i.c.v.; 17 μg, i.t.; 50 μg, i.pl.) in Chrna6 and Chrna4 null 
mutants after neuropathic (CCI) or inflammatory (CFA) injury. All routes of administration 
produced robust reversal of both types of mechanical allodynia in both wildtype lines at 
these doses (Fig. 5). Supraspinal nicotine anti-allodynia was significantly reduced in Chrna6 
mutants (CCI: t9 = 4.9, p<0.001; CFA: t10 = 2.3, p<0.05), and completely abolished in 
Chrna4 mutants (CCI: t8 = 4.1, p<0.01; CFA: t10 = 3.5, p<0.01) (Fig. 5A). By contrast, 
spinal nicotine anti-allodynia was abolished in Chrna6 mutants (CCI: t20 = 5.7, p<0.001; 
CFA: t9 = 3.2, p=0.01), and preserved in Chrna4 mutants (CCI: t8 = 1.9, n.s.; CFA: t10 = 2.0, 
n.s.) (Fig. 5B). Similarly, anti-allodynia resulting from injection of nicotine directly into the 
hind paw was abolished in Chrna6 mutants (CCI: t10 = 6.4, p<0.001; CFA: t10 = 3.7, 
p<0.01), and preserved in Chrna4 mutants (CCI: t8 = 0.6, n.s.; CFA: t10 = 1.7, n.s.) (Fig. 
5C). These data suggest that nicotine blocks mechanical allodynia in the periphery and/or 
spinal cord in a wholly α6-specific manner, except supraspinally, where both α6* and α4* 
nicotinic receptors appear to contribute.
Electrophysiological measurement of α6* and P2X2/3 receptor interactions
An anti-allodynic effect of α6* activation (after DRG gene expression) suggests a functional 
interaction between α6* nAChRs and another pain-relevant molecular target in the spinal 
cord or periphery. Previous data show that several subtypes of nAChRs interact, both 
functionally and physically, with several subtypes of P2X receptors (20–22). We therefore 
considered the hypothesis that α6* nAChRs interact with P2X2 and P2X3 receptors, known 
to be involved in pain (23, 24), and, like α6* nAChRs (see Fig. 2), to be expressed in the 
IB4-positive subpopulation of nociceptors (24).
We tested three combinations of nAChR subunits (α6β4, α6β4β3 and α6β2), co-expressed 
with most of the possible combinations of P2X2 and P2X3 subunits (P2X2, P2X3, and 
P2X2/3 receptors). Most α6* nAChRs yield very small agonist-induced current in 
heterologous expression experiments, vitiating accurate measurements; we overcame these 
problems by using gain-of-function α6 subunits (α6(L9’S) for α6β4 (10), or gain-of-
function β3 subunits (β3-(V13’S) for α6β4β3 (25), or the combination 
α6(L9’S)β2(L9’S)LFM/AAQA (26). P2X2 receptors and P2X2/3 receptors express robustly in 
oocytes; the latter are activated selectively by α,βme-ATP (27).
With seven of the eight combinations of α6* receptors and P2X receptors studied we found 
functional interactions, in the form of cross-inhibition between these two classes of ligand-
gated receptors. In the first type of interaction, when ACh and ATP are co-applied, the 
agonist-induced currents are less than the sum of individual currents. This type of interaction 
was previously observed between P2X receptors and several other pentameric receptors. 
When α6* nAChRs were expressed alone, they showed no direct responses to ATP; the 
addition of ATP (320 μM) produced < 15% change in the ACh-evoked currents at any 
concentration. We found as well that P2X2, P2X3, or P2X2/3 currents were not affected by 
ACh (100 μM). In four of the six cases where we could study dose-response relations, we 
found only minor (<2-fold) changes in the EC50 values for each agonist when we co-
expressed these receptors (table S4); an exception is described below. Despite these minimal 
interactions at the dose-response levels, when ACh and ATP are co-applied, the agonist-
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induced currents are less than the sum of individual currents (Fig. 6A–C). This pattern was 
observed with all types of α6* nAChR expressed with P2X2 (table S4), or with P2X2/3 
receptors (Fig. 6A–C). Cross-inhibition was also observed between α6(L9’S)β4 and 
P2X3(K65A) receptors (28); the P2X3(K65A) mutation was employed because it decreases 
the rate of desensitization (29).
A second type of cross-talk occurs between α6β2 or α6β4 nAChRs and P2X receptors. The 
presence of co-expressed α6* nAChRs changes the dose-response relation of the P2X3 
receptor (28). This type of interaction has been previously reported only for the interaction 
between α3β4 nAChR and P2X2 (22). The EC50 of the P2X3 receptor is 2–3-fold higher, 
and the response has decreased apparent cooperativity, revealed by a reduced Hill 
coefficient. As a result, responses to ATP in the concentration range 10–100 μM are reduced 
by approximately half to two-thirds, when normalized to maximal responses. These data are 
summarized in table S4 [see also (28)].
FRET measurement of interaction between α6* and P2X3 receptors
We tested for physical interactions between α6β4* nAChRs and P2X receptors in cultured 
mouse cortical neurons, using FRET as previously performed for P2X2 and α4β2 nAChRs 
(20). FRET typically reveals interactions between fluorophores that are less than 80 Å apart, 
implying a macromolecular complex. We tested for interactions between eYFP- and 
mCherry-labeled receptors, using fluorescence life time imaging microscopy. Results show 
that P2X3 and α6β4 receptors physically interact, with a FRET efficiency of ≈50% (fig. S6) 
and a binding fraction of ≈40%.
We tested FRET with and without incorporation of non-fluorescent β3 subunit into the α6β4 
receptor (fig. S6B,C). The incorporation of β3 did not alter the binding fraction or the FRET 
efficiency. To test whether the β3 simply did not become incorporated into the α6β4 
receptor, we measured FRET in cells transfected with α6, β3-eYFP, and β4 subunits and 
with P2X3-mCherry receptors where the fluorophores were located on the β3 and P2X3. 
This resulted in FRET efficiency of ≈50%, indicating that the incorporation of the β3 
subunit does not change the FRET efficiency between P2X3 and α6-containing nAChRs. 
Because some of the electrophysiological data were obtained using the gain-of-function α6 
mutant, FRET imaging was also performed in the mutant, expressed with β4-eYFP subunit 
and P2X3-mCherry. The FRET obtained with α6(L9’S)β4 receptor with P2X3 did not differ 
statistically from the data obtained with the wild type α6 subunit. A range of control 
experiments (including FRET determination of soluble eYFP and P2X3-mCherry, P2X3-
eYFP and α6-mCherry, P2X3-eYFP and β4-mCherry, and P2X3-eYFP and plasma 
membrane anchored mCherry) were negative.
Behavioral measurement of α6* and P2X2/3 receptor interactions
As P2X3 receptors mediate both neuropathic and inflammatory pain (23, 24), and there is 
precedent for the ability of a protein (P2X7) to affect pain indirectly via downregulation of 
P2X3 receptors (30), we assessed whether P2X3-dependent pain could be affected by 
activation of α6* receptors, as suggested by the observed cross-inhibitions in a heterologous 
expression system. The P2X3 agonist, α,βme-ATP, injected into the hind paw produced 
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frank nocifensive (licking) behavior of equivalent intensity in all three genotypes (Fig. 7A). 
The pain behavior was dose-dependently reversed by systemic nicotine in WT (F3,18=9.1, 
P<0.001) and L9’S mice (F3,11=6.1, P=0.01), as well as the P2X3 receptor antagonist 
A-317491 (t10=4.6, P<0.001). In Chrna6 KO mice statistically significant reversal 
(F3,28=3.1, P=0.04) was only achieved at the highest dose, and to a lesser degree than in the 
other two genotypes (P<0.01) (Fig. 7A). α,βme-ATP also produced A-317491-reversible 
mechanical allodynia of equal magnitude in the three genotypes, which was completely 
reversed by nicotine (0.9 mg/kg) in L9’S mice, partially reversed in WT mice, and 
unaffected by nicotine in KO mice (P<0.05 compared to L9’S) (Fig. 7B).
CHRNA6 and variable chronic pain in humans
A human cohort of 429 adults who underwent herniotomy (31) was genotyped at three 
CHRNA6 polymorphisms that cover haplotypic diversity in the gene locus to test association 
of the gene with clinical pain. One promoter region SNP (rs7828365) was found to be 
associated with changes in pain susceptibility under a recessive inheritance model, in which 
the minor allele homozygote (TT) showed an increased risk of persistent pain at 6 months 
post-surgery (odds ratio=12.0, standard error=1.1, P=0.03; Fig. 8A). Only eight TT 
homozygotes were present in the cohort, and thus the association P-value was computed by 
a permutation t-test, which is robust in the presence of small expected counts. To replicate 
this finding, we genotyped rs7828365 in another cohort where the clinical pain phenotype 
was thoroughly characterized, a cohort a cohort of 159 Caucasian females with TMD (32). 
Although only two individuals were TT homozygotes, in agreement with findings from the 
post-surgical pain cohort these TT-carrying TMD patients experienced substantially higher 
intensity and greater duration of clinical head and orofacial pain symptoms on a normalized 
composite score incorporating multiple domains of the Chronic Pain Symptom 
Questionnaire (33). The pain increase was significant as tested by a permutation t-test 
(P=0.03; Fig. 8B). This cohort was also tested for association with SNPs in the CHRNA4 (3 
SNPs), CHRNA5 (8 SNPs) and CHRNB2 (2 SNPs) genes; no P-value was lower than 0.40.
To estimate the overall effect of the genotype TT on chronic pain in human subjects, results 
of the two human studies were combined, yielding P=0.002, which remains significant 
(P=0.02) after adjusting for three SNPs and three inheritance models examined.
DISCUSSION
The current studies reveal, via expression genomics performed in the mouse, an unexpected 
role of the Chrna6 gene and α6* receptors in mediating mechanical allodynia after nerve 
injury or inflammation, and in the reversal of such mechanical allodynia by nicotine. We 
show that: a) α6* receptors are expressed in a subset of nociceptors within the DRG; b) 
Chrna6 expression in the DRG correlates with mechanical allodynia across mouse strains; c) 
mutant mice showing null- or over-expression of Chrna6 display more and less mechanical 
allodynia, respectively; and, d) nicotine’s spinal and peripheral anti-allodynic effects are 
mediated by α6* rather than α4* receptors, although both subunits participate in supraspinal 
effects of nicotine. Further, we have defined a plausible mechanism (although not 
necessarily the only one) whereby α6* receptors can ameliorate chronic pain, via cross-
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inhibition with P2X2/3 receptors facilitated by direct contact between the proteins, 
demonstrated in vitro and behaviorally. Nicotine may be employing this α6*- and P2X2/3-
dependent mechanism to produce pain relief, although the statistically significant (but 
incomplete) analgesia at 1.35 mg/kg in Chrna6 null mutants suggests that alternative 
mechanisms may also be recruited.
In addition, we have demonstrated the relevance of the CHRNA6 gene in humans; the fact 
that TT homozygotes report substantially higher clinical pain in two very different chronic 
pain disorders reinforces the notion that α6* receptors are playing a similar role, 
qualitatively, in pain biology in mice and humans. The rare frequency of the TT genotype 
suggests that CHRNA6 is not a primary explanation of chronic pain variability in our species 
as it appears to be in the mouse. This is very likely simply due to species differences in 
frequencies of the trait-relevant alleles. The utility of rare variants in the validation of 
molecular targets for pain is well accepted (34, 35). Nonetheless, the highly limited sample 
size of TT homozygotes in the present study represents a limitation of the human genetic 
findings. The true role of CHRNA6 in pain awaits investigation in more highly powered 
cohorts.
After the discovery of the remarkably high analgesic potency of the frog alkaloid, 
epibatidine (36), pioneering investigations on epibatidine analogs were interpreted in terms 
of agonism of α4β2* nAChRs (37, 38). Preclinical and limited clinical evidence do suggest 
that α4β2* subtypes play an important role in nociception. α4β2* nAChRs are expressed in 
many CNS regions that modulate pain transmission and α4β2* agonists induce increases in 
inhibitory tone in the spinal cord. Several high affinity α4β2* nAChR agonists were 
reported to have potent analgesic activity in rodent models of acute and chronic pain. 
Furthermore, evidence from studies using KO mice for the α4* and β2* nicotinic subunits 
showed the dependency of nicotinic analgesia on this subtype (39), although we note that 
this conclusion was largely based on nicotine inhibition of acute, thermal pain. Much less is 
known about the composition of other nAChRs mediating analgesia. Various additional 
nAChR subunits, including α5, α6, α7, β3, and β4 subunits participate in subtypes (for 
example α4α6β2*, α6β2*, and α6β4*) which have been identified in the spinal cord and 
DRG tissues. Previous pharmacological and genetic evidence has challenged the assumption 
that the α4β2 subtype is the main analgesic target (40–43), as does the recently reported 
clinical trial failure of ABT-894 (44).
The present observations suggest that α6* nicotinic receptors produce their analgesic effects 
by cross-inhibition of P2X2/3 receptors involving direct contact between the proteins. Other 
nAChR–P2X receptor interactions increase with the densities of the receptors (21). The 
details of the contacts, the receptor states involved, and the possible roles of ion flux are not 
fully known; but modifications to desensitization could play a role (28, 45). Purinergic 
receptors are important pain processing molecules known to be expressed on nociceptive 
small diameter neurons in the DRG (46), with important roles having been demonstrated for 
P2X2/3 (23, 24, 47), P2X4 (48), and P2X7 (49). P2X2/3 receptors have been shown to 
contribute to multiple pain modalities, including inflammatory pain (23, 24, 47, 50), 
neuropathic pain (51), visceral pain (52), musculoskeletal pain (53), cancer pain (54), and 
migraine (55). Presumably the α6* nicotinic receptors interacting in the periphery with 
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P2X2/3 receptors are activated endogenously by acetylcholine, which exists abundantly in 
mammals both neuronally and non-neuronally, for example in keratinocytes (56). Expression 
levels of choline acetyltransferase in mouse epidermis exceed that of any other tissue 
(biogps.org). Furthermore, experiments examining the pharmacokinetic profile of A-317491, 
and using the rat skin-nerve preparation, have suggested a peripheral site of action of 
P2X2/3 receptors on pain processing (57).
Our current data demonstrate that, in both chronic inflammatory and neuropathic pain 
models, nicotine blocks mechanical allodynia—a more important clinical symptom (58) than 
the acute thermal pain that has been often studied in this area—in an α6*-specific manner, 
and that the role of α4* in this phenomenon is limited or absent, except in the supraspinal 
compartment. It is therefore possible that the modest efficacy of some α4β2* agonists 
reported in animal models of chronic inflammatory pain (43) and initial clinical studies (38) 
may be related to their insufficient binding and/or functional activity at α6* subtypes, 
including both α6β2* and α6β4* subtypes studied here; Hone et al. (12) found that the 
latter have larger responses to ACh. In fact, a very recent paper shows equal binding affinity 
of ABT-894 to α6β2* and α6β4* nAChRs in monkey striatum (59), but functional 
selectivity and efficacy were not reported. We believe that the refocusing of nAChR 
analgesic development on α6*-containing receptors could lead to much more efficacious 
compounds, which due to the comparatively limited distribution of Chrna6 expression 
should display a favorable side-effect profile compared to current drugs. Peripheral targeting 
of such compounds would make them even more attractive, as our findings suggest that 
efficacy would be preserved while side-effects—for example related to enhanced dopamine 
release (60) and engagement of brain reward pathways (61)—would be reduced yet further. 
Development of α6*-acting drugs for the treatment of Parkinson’s disease and nicotine 
addiction have been hampered by the inability to achieve heterologous expression of α6*-
containing receptors and designing ligands that discriminate α6* from α3*, but mutation-
based improvements have recently been reported (62, 63). Our findings do reveal a potential 
side effect of α6* antagonists being contemplated for the treatment of tobacco addiction 
(64).
MATERIALS AND METHODS
Study Design
This study represents a series of experiments using multiple techniques—including genetics, 
pharmacology, and electrophysiology—in Xenopus oocytes, mice and humans. All in vivo 
studies and tissue harvests were performed in accordance with national and institutional 
guidelines, and were approved by animal care and use committees at McGill University, 
Virginia Commonwealth University and the California Institute of Technology. In 
pharmacological studies, mice were assigned to experimental groups using within-cage 
randomization. Blinding to genotype was in general not possible because of coat color 
variation; experimenters were however blinded to drug and dose. Power analyses were in 
general not possible because the effect size of genotype and drug effects were not 
predictable a priori; sample sizes in this study are consistent with norms in the field (65). 
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Data from three mice in the strain survey were omitted from further analysis because they 
were identified as statistical outliers (Studentized residual > 3).
Mice
Mice in the 25-strain survey were naïve, adult (6–14 week old) mice of both sexes obtained 
from The Jackson Laboratory. Strains included: 129S1, A, AKR, BALB/cBy, BTBR T+ tf, 
BUB/Bn, C3H/He, C57BL/6, C57BR/cd, C58, CBA, DBA/2, FVB/N, KK/Hl, MRL/Mp, 
NOD/Lt, NON/Lt, NZO/HlLt, NZW/Lac, P, PL, RIIIS, SJL, SM and SWR; all “J” 
substrains. Mouse strains used in the Persson et al. (2) experiment, some of whose results 
are reanalyzed here, included AKR/J, C3H/HeJ, C57BL/7J, C58/J, and CBA/J. Subjects of 
all subsequent experiments were naïve, adult (6–14 week old) C57BL/6J mice bred in our 
vivarium from breeders obtained from The Jackson Laboratory, mice with L9’S gain-of-
function of α6* nAChRs and their wildtype (WT) controls (10), transgenic Chrna6 null 
mutant (KO) mice and their WT controls (19), α6*-GFP BAC transgenic mice (11), or 
Chrna4 (α4*) KO mice and their WT controls (66). All mutants have been bred fully 
congenic (>10 generations) to C57BL/6. All mice were housed in standard polycarbonate 
cages in groups of 2–5 same-sex littermates in a temperature-controlled (20 ± 1 °C) 
environment (14:10 h light/dark cycle; lights on at 07:00 h); tap water and food (Harlan 
Teklad 8604) were available ad lib.
Microarray gene-expression profiling
DRGs were dissected from naïve 2-month-old mice of both sexes (n=3 mice/sex/strain) 
between 09:00–12:00 h. Total RNA was isolated from tissues using Trizol (Invitrogen) 
followed by RNeasy (Qiagen, Valencia, CA). RNA quality was examined on an Experion 
(BioRad) instrument. cDNA and amplified antisense RNA was made from 1.4 μg of pooled 
total RNA, using the Affymetrix Single Amplification protocol. Affymetrix MOE430v2 
arrays were hybridized, washed, stained, and scanned using standard Affymetrix protocols.
Haplotype mapping
Haplotype association mapping was done as described (17, 67). Briefly, local haplotypes 
were computed for all inbred mouse strains by analyzing a sliding window of SNP 
genotypes. Strains were grouped based on haplotype group assignment, and the F-statistic 
was used to quantify the association between that local haplotype and the phenotype of 
interest. The significance of that F-statistic was computed non-parametrically based on a 
weighted bootstrap method that accounted for the inherent population structure in the panel 
of inbred mouse strains (17).
Quality control was achieved as follows. Total RNA samples were only used for pools if the 
28S rRNA bands were at least twice the intensity of 18S rRNA bands. Arrays were only 
included in the final dataset if the following metrics from the Affymetrix MAS5 algorithm 
were met: 1) percent present calls ≥40; and 2) scaling factors, percent present calls, and 
background were all within two standard deviations of the mean. Signal intensity 
histograms, displayed in the MAS5 software, contained no outliers when observed visually. 
Hierarchical clustering of samples was also examined for outliers which might indicate 
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arrays and RNA with good quality but from poorly dissected tissue; there were no such 
outliers.
Immunofluorescence
Adult male α6*-GFP transgenic mice were perfused with 4% PFA and DRGs from all levels 
were quickly dissected. The DRG were post-fixed overnight in 30% sucrose and embedded 
in OCT. DRGs were sectioned with a cryostat at 10-μm thickness and mounted on super 
frost plus slides and stored at −80 °C.
Frozen slides were air dried at room temperature for 1 h. Slides were blocked for 1 h at room 
temperature in PBS plus Triton X-100-containing 3% BSA and 10% goat serum or donkey 
serum, and overnight at 4 °C with primary antibodies diluted in the blocking solution. The 
primary antibodies used were: 1:500 rabbit anti-GFP (Life Technologies, Cat. A11122), 
1:150 goat anti-GFP (LifeSpan Biosciences; Cat. LS-C48996), 1:1000 rabbit anti-CGRP 
(Abcam; Cat. ab-47027); 1:500 rabbit anti-NF200 (Sigma; Cat. N4142). The sections were 
then washed three times in PBS with Triton X-100 and incubated at room temperature for 1 
h with secondary antibodies conjugated to Alexa-488 or 568 fluorochromes (Life 
Technologies) diluted 1:200 in blocking solution. To detect IB4 staining, GS-IB4-Alexa 568 
(Life Technologies, Cat. I21412) was diluted 1:200 and incubated during secondary 
antibody incubations. Sections were then washed three times in PBS with Triton X-100 and 
mounted in SlowFade gold anti-fade medium with DAPI (Life Technologies).
Image Acquisition and Quantification
Fluorescence images were acquired using an AX70 microscope (Olympus). Images were 
taken using identical acquisition parameters and raw images were analyzed with Metamorph 
software. Neurons were considered GFP-positive if the mean fluorescence intensity, 
measured as arbitrary units, was higher than the mean background fluorescence. This was 
set as the threshold to include all the GFP-positive cells. Regions were drawn around the 
GFP-positive cells and these regions were transferred over to the other sensory marker to 
image co-expressing neurons. Cells were considered positive for NF200, IB4 or CGRP if the 
mean fluorescence intensity was higher than the mean background fluorescence.
Real-time qPCR
For tissue comparison experiments, DRGs were freshly isolated from adult male C57BL/6J 
mice and snap frozen on dry ice, and total RNA was isolated using Trizol treatment. Total 
RNA from all other tissues was purchased from Zyagen. For strain comparison experiments, 
DRGs from different inbred strains were isolated (n=3 mice/sex/strain) and treated similarly. 
Two hundred ng of total RNA was used to generate the first-strand cDNA using the 
Quantitect Reverse transcript kit (Qiagen). A real time Taqman PCR assay for Chrna6 
(Assay ID: Mm00517529_m1) was purchased from Life Technologies, with a FAM reporter 
dye and a non-fluorescent quencher. FastStart Universal probe master mix (Rox) from Roche 
Diagnostics was used. The reaction was run, in triplicate, in the ABI 7900HT fast real time 
system using 0.5 μl of the cDNA in a 10-μl reaction as per the manufacturer’s instructions.
Wieskopf et al. Page 12
Sci Transl Med. Author manuscript; available in PMC 2016 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Calibrations and normalizations were done using the 2−∆∆CT method. The target gene was 
Chrna6, while the reference gene was Actb (β-actin). The calibrator for the tissue 
comparisons was the DRG; the calibrator for the strain comparisons was the DBA/2 strain.
Oocyte Expression and Analysis
Rat α6, rat β2, and mouse β3 nAChR subunits were in the pGEM vector, and rat β4 nAChR 
was in the pAMV vector. All P2X cDNAs were in the pcDNA3 vector. Site-directed 
mutagenesis was performed using the Stratagene QuikChange protocol and verified through 
sequencing. Circular cDNA was linearized, then used as a template for in vitro transcription. 
Stage V–VI Xenopus laevis oocytes were injected with 50 nl of mRNA solution. To express 
the α6β4 combination, we used a hypersensitive α6 subunit containing a serine mutation at 
the leucine9’ in the M2 domain (residue 279). To express the α6β4β3 combination, we used 
the wild-type α6 and β4 in combination with the hypersensitive β3 containing a serine 
mutation at the valine13’ in M2 (residue 283). When α6β4* nAChR and P2X receptors were 
co-expressed, equal volumes of corresponding mRNA solutions were mixed prior to the 
oocyte injection. To express the α6β2 combination, we used the hypersensitive α6 subunit, 
as well as a hypersensitive β2 subunit containing a serine mutation at the leucine9’ in M2 
and two endoplasmic reticulum export-enhancing mutations (26). To study P2X3, we used 
the K65A mutation, which accelerated the rate of recovery from desensitization. The 
α6β2P2X2:α6Lβ2P2X3 mRNA injection ratios were 10:10:1 and 1:1:1 respectively, at 5 ng/
oocyte total mRNA. P2X2/3 was expressed by co-injection of 1:10 ratio of P2X2:P2X3 
mRNA. After mRNA injection, oocytes were incubated for 12–72 h at 18 °C in culture 
medium (ND96+ with 5% horse serum).
Two-electrode voltage-clamp recordings used the OpusXpress 6000A (Axon Instruments). 
For cross-inhibition experiments on P2X3(K65A), the concentration of ATP was 100 μM for 
cells expressing P2X3(K65A) and α6β4β3(V13’S) or 320 μM for P2X3(K65A) and 
α6(L9’S)β4. To investigate cross-interaction between P2X2/3 receptor and α6β4* nAChRs, 
the P2X2/3 receptor was activated by 100 μM α,βme-ATP, and the α6* nAChR by 100 μM 
ACh. Peak currents from at least three traces were averaged from the same cell for data 
analysis.
All dose-response data were normalized to the maximal current (Imax = 1) of the same cell 
and then averaged. EC50 and Hill coefficient (nH) were determined by fitting averaged, 
normalized dose-response relations to the Hill equation. Dose-response relationships of 
individual oocytes were also examined and used to determine outliers.
For all cross-interaction data involving P2X2 or P2X2/3, the predicted current from agonist 
co-application was calculated from the arithmetic sum of IACh and IATP (or Iα,βme-ATP) from 
the same cell. The actual, observed current upon co-application of the agonists was 
subtracted from the prediction value of the same cell, and this difference was designated as 
the Δ. All current data and Δ were normalized to the prediction value of the same cell, and 
then the normalized data were averaged across ≥ 7 cells from ≥ 2 batches of oocytes.
For all cross interaction data on the P2X3(K65A) receptor, co-application of the agonists 
used the “prolonged plus brief pulse” protocol (28). Averaged ATP-evoked peak current 
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during ACh application (IATP*) was subtracted from averaged ATP-evoked current in the 
absence of ACh (IATP) from the same cell to obtain a Δ*. All current data and Δ* were 
normalized to (IATP) and averaged across ≥ 8 cells from ≥ 2 batches of oocytes.
Neuronal Cultures
Cortical neurons were extracted from day 17 mouse embryos and plated on 35-mm Mattek 
polylysine-coated glass bottom culture dishes in a neuronal medium containing Neurobasal, 
B27 (Invitrogen), and Glutamax supplemented with 3% equine serum. Neurons were plated 
at a density of 60,000 cells per dish. On day 4 of culture, neurons were treated with 1 μM 
cytosine arabinoside. Neurons were maintained via 50% exchange with feeding medium 
(Neurobasal, B27, and Glutamax) twice per week. On day 7 in culture, plasmids were mixed 
in 100 μl of OptiMEM, although 4 μl of Lipofectamine-2000 was mixed with a separate 100 
μl aliquot of OptiMEM. After 5 min at 22 °C, the separate solutions were mixed together 
and kept at room temperature for an additional 25 min. Neurons were transfected with 500 
ng of each nAChR plasmids (α6, β3 and β4) and 1000 ng of P2X3 plasmid wild type or 
labeled with fluorescent protein. After 3 h at 37 °C, transfection medium was replaced with 
neuronal feeding medium.
FRET Analysis
Mouse E17 cortical neurons were transiently transfected with the indicated constructs on 
day 5 in culture, and measurements were made 1–3 days later. Before an imaging session, 
cell culture medium was replaced with phenol red to n2-independent Leibovitz (L-15) 
medium (Invitrogen). FRET was analyzed by fluorescence lifetime imaging microscopy 
(FLIM) using a 60x oil immersion objective on a C1si laser-scanning confocal microscope 
(Eclipse; Nikon) equipped with a 60r-scanning confocal microscope. Samples were scanned 
at a rate of 6 μs per pixel for a 256 × 256 pixel image. A 480 nm picosecond pulsed diode 
laser (PDL 800-D, PicoQuant GmbH) provided the excitation light (40 MHz), and emitted 
light was directed to a single-photon photomultiplier (SPCM-AQR SPAD; Perkin Elmer). A 
time-correlated single photon counting module and event timer (PicoHarp 300, PicoQuant 
GmbH) was used to record photon arrival times. Histograms of the time delay between the 
laser excitation pulse and photon arrival events were fit to exponential decays to extract 
fluorescence lifetimes for each pixel using PicoHarp 2.0, SymPhoTime software. The 
extracted lifetimes were used to determine the FRET efficiency (E) where E= 1- τda/τd (τd = 
donor lifetime in the absence of the acceptor and τda = donor lifetime in the presence of the 
acceptor). Binding fractions were determined from the coefficients of each exponential 
component in the fit.
Nociceptive Assays
von Frey Test—In the strain survey, mice were tested on the von Frey test using the up-
down staircase method of Dixon (68). Mice were placed on a metal mesh floor within small 
Plexiglas cubicles (9 × 5 × 5 cm high), and a set of eight calibrated von Frey fibers 
(Stoelting Touch Test Sensory Evaluator Kit #2 to #9; ranging from 0.007 g to 1.40 g of 
force) were applied to the plantar surface of the hind paw until they bowed. The presence or 
absence of a withdrawal response in the next 3 s was scored, and determined the next fiber to 
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be applied. In all subsequent experiments, an automated von Frey test was used (Ugo Basile 
Dynamic Plantar Aesthesiometer). In this assay, pressure is gradually increased by the 
device until the mouse withdraws its hind paw; the maximal pressure at that point is 
displayed. We have found this method to feature less variability than the up-down technique. 
Relative strain sensitivities are preserved using both methods (J.S. Mogil, unpublished data). 
In all experiments, measurements were taken in both ipsilateral and contralateral hind paws. 
Except for in Fig. 1A, only ipsilateral hind paw responses are presented. There were no 
significant main effects of surgery, genotype or drug on contralateral hind paw withdrawal 
thresholds in any experiment.
Neuropathic Surgeries—After testing on two separate occasions (averaged) for baseline 
mechanical sensitivity as described above, some mice received experimental surgeries 
featuring damage to peripheral nerves serving the hind paw. In different studies either the 
spared nerve injury (SNI) (69, 70), spinal nerve ligation (SNL) (71), or chronic constriction 
injury (CCI) (72) was used. In the SNI we spared the sural nerve, and thus von Frey testing 
occurred on the lateral aspect of the hind paw. Mice were retested for mechanical sensitivity 
on postoperative days 1, 4, 7, 14, 21 and 28 in experiments evaluating allodynic severity, and 
on day 7 in experiments evaluating drug anti-allodynia. In the latter, (−)-nicotine (Sigma) 
was injected either systemically (0.15–1.8 mg/kg, i.p.), intracerebroventricularly (2.5–25 μg, 
i.c.v.; (73), intrathecally (1–17 μg, i.t.; (74), or subcutaneously into the mid-plantar hind paw 
(25–100 μg; intraplantar; i.pl.) immediately after “baseline” testing on day 7, and retested 
15, 30, 45 and 60 min later. In the experiment shown in Fig. 5e, mice were retested 5, 15 and 
30 min after i.t. nicotine injection.
Inflammatory Assay—After testing on two separate occasions (averaged) for baseline 
mechanical sensitivity as described above, mice were injected with complete Freund’s 
adjuvant (CFA; 50%; Sigma) into one hind paw. Mice were retested 3, 5, 7, 9 and 11 days 
post-injection in experiments evaluating allodynic severity, and on day 3 in experiments 
evaluating drug anti-allodynia. In the latter, (−)-nicotine (Sigma) was injected either 
systemically (0.30–1.8 mg/kg, i.p.), intracerebroventricularly (2.5–25 μg, i.c.v.; (73), 
intrathecally (1–17 μg, i.t.; (74), or subcutaneously into the mid-plantar hind paw (25–100 
μg; intraplantar; i.pl.) immediately after “baseline” testing on day 3, and retested 15, 30, 45 
and 60 min later. In the experiment shown in Fig. 5e, mice were retested 5, 15 and 30 min 
after i.t. nicotine injection.
α,βme-ATP-induced Pain Behaviors—In some experiments, mice pretreated 20 min 
earlier with nicotine (0–1.35 mg/kg, i.p.) or A-317491 (300 nmol, i.pl.; Tocris Bioscience) 
were injected with 40 nmol of α,βme-ATP (Tocris) into one hind paw, and nocifensive 
licking/biting behaviors were measured over the next 60 min by sampling the first 10 s of 
every 1-min time period. In other experiments, mice were tested for mechanical sensitivity 
as described above immediately prior to and 15 min after 40 nmol α,βme-ATP (to confirm 
the presence of mechanical allodynia), followed immediately by systemic injection of 
nicotine (0.9 mg/kg) or A-317491 (300 nmol, intraplantar). Mechanical sensitivity was then 
measured at 15, 30, 45, 60, 90 and 120 min post-drug.
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Pain Test Battery—Details of the battery of acute and tonic assays are provided in Mogil 
et al. (65).
Quantification of Allodynia and Anti-allodynia—Allodynia over the multiple testing 
days was calculated as area over the withdrawal threshold × time curve using the trapezoidal 
rule; percentage of maximum possible allodynia (% allodynia) was calculated for each 
mouse as compared to a hypothetical subject with the same baseline threshold and maximal 
allodynia (i.e., a threshold of 0 g) at all post-surgery or post-CFA time points.
Drug anti-allodynia over 60 min was calculated as area under the curve using the trapezoidal 
rule, with respect to the pre-injury (pre-surgery or pre-CFA) baseline and the pre-drug (post-
surgery or post-CFA) baseline. Percentage of maximum possible anti-allodynia (% anti-
allodynia) was calculated for each mouse as compared to a hypothetical subject with the 
same pre-injury and pre-drug baseline thresholds and complete resolution of allodynia at all 
post-drug time points.
Human Clinical Cohorts
Persistent Post-herniotomy Pain Cohort—This prospective cohort was comprised of 
429 Danish (n=242) and German (n=187) adult male patients of Caucasian origin (mean 
age: 55.1 years; SD=13.3) who underwent open or laparoscopic transabdominal pre-
peritoneal elective groin hernia repair (31). The main outcome for association analysis was 
the presence of moderate/severe postoperative 6-month pain (yes=46.6%/no=53.4%). There 
was no difference in preoperative nociceptive function assessed by quantitative sensory 
testing between the Danish and the German cohort (31). Genotype-phenotype analysis was 
done using a pre-specified regression equation, incorporating our assumption that one or two 
copies of the rare allele would affect the pain score in different genetic models, and adjusted 
by the following covariates: patients’ age, surgery type and Activity Assessment Scale 
(AAS) score (“0%” if no pain-related activity impairment was reported, and “100%” for 
maximum impairment) at baseline. All subjects donated a blood sample for DNA extraction; 
14 samples could not be confidently assigned to a genotype. The study was approved by 
local ethics committees (Hørsholm Hospital, Denmark and Centre for Minimal Invasive 
Surgery, Germany).
Temporomandibular Disorder (TMD) Cohort—Subjects were non-Hispanic white 
females (n=159), aged 18 to 60 (mean: 36.8 years), recruited for a case-control study at the 
UNC Orofacial Pain Clinic between 2005 and 2009. As described previously (32), TMD 
cases had to report facial pain for at least 5 days during the previous 2 weeks and be 
diagnosed with TMD arthralgia or myalgia during a standardized clinical examination that 
used the Research Diagnostic Criteria for TMD (75). Study participants who completed the 
Chronic Pain Symptom Questionnaire and provided blood for DNA extraction were included 
in this analysis. The CPSQ is a self-report questionnaire designed to ascertain the presence 
and characteristics of multiple pain symptoms, and the lifetime presence of multiple pain 
conditions (33). To derive a single composite value representing pain of the head and neck, 
seven individual responses (duration of facial pain, intensity of current facial pain, intensity 
of greatest pain in the last 6 months, intensity of average pain over the last 6 months, 
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primary headache characteristics, percentage of lifetime suffering from primary headache, 
and count of comorbid pain conditions) were normalized by conversion to z-scores, and then 
summed. All subjects provided signed informed consent for study procedures including 
blood draw and genotypic assessment, and this study was approved by the UNC Biomedical 
Institutional Review Board.
Human Genotyping
Genomic DNA was extracted from each blood sample using QIAamp DNA Bloodkit 
(Qiagen, CA). Three tagging SNPs were identified within CHRNA6 gene locus using the 
Haploview Tagger program: rs892413 (MAF=0.21); rs1072003 (MAF= 0.18), and 
rs7828365 (MAF=0.12). Tagging SNPs were genotyped using the 5’ nuclease method (76) 
and predesigned ABI SNP assays. Allele-specific signals were distinguished by measuring 
endpoint 6-FAM or VIC fluorescence intensities at 508 nm and 560 nm, respectively; 
genotypes were generated using StepOnePlus System Software (Applied Biosystems). The 
genotyping error rate was directly determined by re-genotyping 25% of the samples, 
randomly chosen, for each locus. Data cleaning and analysis were implemented using 
PLINK software v1.07 (77). Standard genotyping quality filters were imposed (call rate 
>95%, Hardy-Weinberg equilibrium P>5×10−5).
Statistical Analyses
Statistical analyses for mouse studies were conducted using an α level of 0.05. ANOVAs or 
t-tests were performed as appropriate after determining the normality of the experimental 
data (Shapiro-Wilk test), followed by Tukey’s or Dunnett’s posthoc tests, as appropriate. 
One-tailed testing was used where a priori expectations of direction of effect (e.g., analgesia 
from a known analgesic compound like nicotine) existed. Analgesic ED50s and associated 
95% confidence intervals were calculated using the method of Tallarida and Murray (78) as 
implemented by the FlashCalc 40.1® macro (M.H. Ossipov, University of Arizona). In 
expression and haplotype genomic mapping studies, multiple testing was controlled using 
false discovery rate.
Due to the small expected counts for TT homozygotes observed in the two human samples, 
permutation t-tests were used to assess significance of genetic associations (79). In the case 
of the herniotomy sample, where the response is binary, the usage of the t statistic in 
permutations is equivalent to the permutation test based on the χ2 statistic (80). Association 
P-values for two human studies were combined by a modification of the inverse normal 
method (81), where study-specific directional P-values are combined and the result is 
converted to a two-sided P-value.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Correlation of DRG expression of Chrna6 and mechanical allodynia after SNI in inbred 
mice
SNI surgery was performed on 25 inbred mouse strains, and withdrawal thresholds of the 
ipsilateral hind paw to von Frey fiber stimulation were measured. Symbols in A (n=139) 
represent mean ± SEM paw withdrawal threshold on each testing day; bars in B (n=4–6 
mice/strain) represent mean ± SEM percentage of maximum possible allodynia (see 
Materials and Methods online). (C) The top 7 correlations (Pearson’s r; all P<0.005) 
between the strain means shown in B and basal DRG expression levels of ≈45,000 probesets 
in these same strains. (D) The correlation between allodynia and basal DRG expression (in 
arbitrary units) of probeset 1450426_at (Chrna6); symbols represent individual strain values. 
Symbol abbreviations are self-explanatory except for: Bc, BALB/cBy; B6, C57BL/6; BR, 
C57BR/cd; D2, DBA/2. (E) Average expression across all strains of all Chrn* genes. Bars 
represent basal DRG expression (in arbitrary units) ± SD.
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Fig. 2. Chrna6 mRNA expression in a subset of DRG neurons
DRG neurons from adult α6*-GFP mice were stained with antibodies against GFP (green) 
and sensory neuron markers NF200 (A), IB4 (B) and CGRP (C) (all red). Arrows indicate 
neurons expressing either GFP or the sensory marker. Filled arrow heads indicate neurons 
co-expressing both markers. Scale bars= 100 μm.
Wieskopf et al. Page 24
Sci Transl Med. Author manuscript; available in PMC 2016 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. Differential mechanical allodynia after nerve injury and chronic inflammation in Chrna6 
mutant mice
Increased mechanical allodynia after SNI surgery (A,B) and CFA injection (C,D) in Chrna6 
KO mice, and decreased mechanical allodynia after SNI (E,F) and CFA (G,H) in Chrna6 
L9’S gain-of-function mutants. In all graphs, symbols (n=5–12 mice/genotype) represent 
mean ± SEM paw withdrawal threshold (g) on each testing day; bars represent mean ± SEM 
percentage of maximum possible allodynia (see Materials and Methods). *P<0.05, 
**P<0.01, ***P<0.001 compared to other genotype. A replication of the KO data, using a 
different neuropathic assay, can be found in fig. S4.
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Fig. 4. Altered anti-allodynic potency and efficacy of nicotine in Chrna6 mutant mice
Shown are dose-response relationships for the ability of systemic (i.p.; A,B), 
intracerebroventricular (i.c.v.; C,D), intrathecal (i.t.; E,F), and peripheral (intraplantar; i.pl.; 
G,H) nicotine to reverse already-developed (and maximal) mechanical allodynia produced 
by SNI (day 7 post-surgery; A,C,E,G) and CFA (day 3 post-injection; B,D,F,H). Symbols 
(n=4–8 mice/dose/genotype) represent mean ± SEM percentage of maximum possible anti-
allodynia, based on the pre-SNI/CFA and post-SNI/CFA withdrawal thresholds of each 
mouse (see Materials and Methods). Statistical analyses are shown in table S3.
Wieskopf et al. Page 26
Sci Transl Med. Author manuscript; available in PMC 2016 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 5. Dependence of spinal and/or peripheral nicotine anti-allodynia on α6
A head-to-head comparison of supraspinal (25 μg, i.c.v.; graph A), spinal (17 μg, i.t.; graph 
B) and peripheral (50 μg, i.pl.; graph C) nicotine anti-allodynia against neuropathic (CCI) 
and inflammatory (CFA) pain in Chrna6 (α6*) and Chrna4 (α4*) WT and KO mice tested 
using identical parameters at the peak of allodynia (14 days post-CCI, 3 days post-CFA). 
Bars (n=5–6 mice/genotype/injury) represent mean ± SEM percentage of maximum possible 
anti-allodynia (see Materials and Methods). **P<0.01, **P<0.01, ***P<0.001 compared to 
analogous WT.
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Fig. 6. Electrophysiological detection of crosstalk between P2X and α6* receptors in Xenopus 
oocytes
(A) Co-expressed P2X2/3 and α6β4 receptors; (B) co-expressed P2X2/3 and α6β4β3 
receptors. Exemplar inward currents are shown, evoked with 100 μM α,βme-ATP, 100 μM 
ACh, or a mixture of 100 μM α,βme-ATP+ACh. (C) Co-expressed P2X2 and α6β2 
receptors were tested with 100 μM ATP, 10 μM ACh, or a mixture of the two agonists. All 
graphs summarize experiments from n = 11–13 cells. The ‘predicted’ (Pred.) current for 
each cell is the arithmetic sum of the Iα,βme-ATP and IACh currents. The ‘Δ’ current for each 
cell is the predicted current minus the observed Iα,βme-ATP+ACh current. Error bars represent 
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SEM. To provide measureable responses, several subunits were mutated as described in 
Methods.
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Fig. 7. Modulation of P2X2/3 agonist-induced pain and hypersensitivity by nicotine in Chrna6 
mutant mice
(A) Intrathecal administration of α,βme-ATP produces nocifensive (licking) behavior 
inhibited by the P2X3 antagonist, A-317491 (300 nmol, intraplantar), and systemic nicotine 
in WT and L9’S but not KO mice. Symbols (n=4–11 mice/dose/genotype) represent mean ± 
SEM samples featuring licking behavior (see Materials and Methods). *P<0.05, **P<0.01, 
***P<0.001 compared to 0 dose within genotype. •P<0.05 compared to other genotypes 
within dose. (B) Intrathecal administration of α,βme-ATP produces mechanical allodynia 
reversed by A-317491 (300 nmol, intraplantar) and nicotine (0.9 mg/kg) in WT and L9’S but 
not KO mice. Symbols (n=4 mice/genotype or drug) represent mean ± SEM paw withdrawal 
threshold at each time point.
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Fig. 8. Human clinical pain is affected by a promoter SNP (rs7828365) in CHRNA6
(A) Percentage of herniotomy patients reporting persistent pain 6 months after surgery, 
stratified by rs7828365 genotype (TT: n=8; TC: n=82; CC: n=325). (B) CPSQ composite 
pain scores (see Materials and Methods) of temporomandibular disorder patients stratified 
by rs7828365 genotype (TT: n=2; TC: n=38; CC: n=117). *P<0.05 compared to other 
genotypes.
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Table 1
Expression of Chrna6 in multiple tissues
Values represent mean ± SEM expression normalized to Actb (β-actin).
Tissue Expression
DRG 0.42 ± 0.06
Eye 0.16 ± 0.01
Whole Brain 0.04 ± 0.02
Lung n.d.
n.d., not detectable
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